Thermo Fisher Scientific (NYSE:TMO) Sets New 52-Week High - Time to Buy?

Key Points

• Thermo Fisher Scientific reached a new 52-week high of $694.33, with shares last trading near $678.89. The stock is trading well above its 50-day and 200-day moving averages.
• The company reported strong quarterly results, with adjusted EPS of $6.03 and revenue of $11.99 billion, beating analyst expectations; revenue increased 10.5% year over year. Analysts maintain a consensus “Moderate Buy” rating, although the average price target of $628.78 is below the current share price.
• Recent growth catalysts include expanded clinical research and pharmaceutical manufacturing capabilities, a new Phase 2 trial agreement through its PPD business, and proteomics research identifying more than 2,500 genetic-protein associations.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report)'s stock price hit a new 52-week high on Tuesday. The company traded as high as $694.33 and last traded at $678.8880, with a volume of 218570 shares. The stock had previously closed at $676.76.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher’s PPD clinical research business signed an agreement with Quantum BioPharma NASDAQ: QNTM to initiate a randomized, placebo-controlled Phase 2 trial of Lucid-MS, a potential treatment for multiple sclerosis. The contract expands PPD’s clinical research work and provides evidence of continued demand for Thermo Fisher’s drug-development services. The financial terms were not disclosed. Thermo Fisher supports Quantum BioPharma multiple sclerosis trial
• Positive Sentiment: At CPHI Milan 2026, Thermo Fisher is showcasing expanded drug-development, manufacturing and clinical capabilities, including its OSD Express solution designed to improve predictability in oral solid-dose manufacturing. The offerings could strengthen the company’s position as pharmaceutical and biotechnology customers seek integrated commercialization support. Thermo Fisher CPHI Milan capabilities announcement
• Positive Sentiment: A collaboration with PRECISE and Nanyang Technological University used Thermo Fisher proteomics technologies to identify more than 2,500 previously unreported genetic-protein associations. The research reinforces the company’s technology credentials and could support future demand for proteomics tools. Thermo Fisher proteomics study announcement
• Neutral Sentiment: JPMorgan reportedly added Thermo Fisher to its October stock picks, while industry commentary highlighted opportunities from generative AI alongside regulatory and adoption risks. These developments may influence sentiment but do not change the company’s financial outlook. JPMorgan October stock picks

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Scotiabank began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an "outperform" rating for the company. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $720.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a "market perform" rating and a $520.00 price objective for the company. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Finally, Piper Sandler began coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They set an "overweight" rating on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $628.78.

Thermo Fisher Scientific Stock Performance

The company has a fifty day moving average price of $620.96 and a two-hundred day moving average price of $536.59. The firm has a market cap of $243.92 billion, a price-to-earnings ratio of 35.31, a price-to-earnings-growth ratio of 2.74 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same period in the previous year, the business earned $4.28 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 over the last three months. Company insiders own 0.33% of the company's stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Large investors have recently made changes to their positions in the business. Legacy Wealth Managment LLC ID increased its stake in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after buying an additional 22 shares during the period. Kilter Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $25,000. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth $26,000. MBM Wealth Consultants LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth $29,000. Finally, Pingora Partners LLC acquired a new stake in Thermo Fisher Scientific during the second quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.